Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Chinheng Chen(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Ronald W. Takvorian(Massachusetts General Hospital), Josie Montegaard(Dana-Farber Cancer Institute), Ephraim P. Hochberg(Massachusetts General Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Leyla Shune(University of Kansas Medical Center), Danielle M. Brander(Duke University), Philippe Armand(Harvard University), James J. Kaminski(Broad Institute), Mohammad Omaira(West Michigan Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Alvaro J. Alencar(University of Miami), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Jeremy S. Abramson(Massachusetts General Hospital), Samuel Y. Ng(National Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 4
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k